Checking Vitals
Update: 2022-12-13
Description
As we close in on the end of 2022, we’ve had the privilege to interview some amazing people who are doing great work with drug discovery.
Join Gina Mullane and Todd Poley as we reflect on some of the memorable moments and guests from this season, including an update on Amylyx Pharmaceuticals’ new ALS treatment, Chris Claussen’s discussion on the positive impacts of psychedelic drugs, and the work of Project ALS to develop a treatment for this crippling disease.
On behalf of our entire team, thank you for listening this year. We hope you’ll join us for an exciting lineup of remarkable stories set to premiere in 2023.
Show Notes:
- Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
- Alzheimer’s Disease Studies
- In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis
- Are Psychedelics the Next Approach to Treating Mental Health Disorders?
- FIRST PERSON LAUNCHES INNOVATIVE PRECISION-TARGETED COGNITIVE SUPPLEMENTS TO ACTIVATE THE FULL POTENTIAL OF HUMAN COGNITION
- The Hermstad Legacy: Advances in Treatments for ALS
- Project ALS
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
